Li Jiatong, Xiao Feifan, Zhang Yuening, Lan Aihua, Song Qian, Zhang Ruoheng, Gu Kailong, Chen Ping, Li Zhuo, Zhang Xinhua, Yang Xiaoli
1 Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, China.
2 Department of Pathophysiology, Guangxi Medical University, Nanning, Guangxi, China.
Technol Cancer Res Treat. 2017 Apr;16(2):159-166. doi: 10.1177/1533034616673272. Epub 2016 Oct 17.
The association between the polymorphic GGN repeat in androgen receptor gene and prostate cancer susceptibility has been studied extensively. But the results of these polymorphisms with prostate cancer risk remain inconclusive. Previous meta-analysis showed short GGN repeats (≤16 repeats) had high risks for prostate cancer compared with longer GGN repeats (>16 repeats). Many studies have been published since the release of the previous meta-analysis. Here, we conducted an updated meta-analysis to demonstrate whether short repeats have higher risks for prostate cancer compared to long repeats. Five databases (PubMed, EMBASE, Cochrane Library, The China National Knowledge Infrastructure, and Web of Science) were last searched until January 1, 2016. Random- or fixed-effects model was performed based on the heterogeneity among studies. The potential publication bias was assessed via Begg funnel plot and Egger regression test. Twelve out of 157 studies were extracted. The result indicated that there was no significant difference between short repeat group and long repeat group in the overall analysis ( I = 80.6%, P = .000, odds ratio = 1.31, 95% confidence interval: 0.93-1.83). There was no association between the length of GGN repeats and the occurrence of prostate cancer in both Caucasian and African American ( I = 6.7%, P = .359, odds ratio = 1.11, 95% confidence interval: 0.94-1.32; and I = 74.1%, P = .050, odds ratio = 0.963, 95% confidence interval: 0.36-2.58). Our result demonstrated that a shorter GGN repeat polymorphism cannot increase the risk of prostate cancer compared to the longer GGN repeats. That's different with previous meta-analysis.
雄激素受体基因中多态性GGN重复序列与前列腺癌易感性之间的关联已得到广泛研究。但这些多态性与前列腺癌风险之间的结果仍无定论。先前的荟萃分析表明，与较长的GGN重复序列（>16次重复）相比，较短的GGN重复序列（≤16次重复）患前列腺癌的风险更高。自上次荟萃分析发布以来，已有许多研究发表。在此，我们进行了一项更新的荟萃分析，以证明与长重复序列相比，短重复序列患前列腺癌的风险是否更高。对五个数据库（PubMed、EMBASE、Cochrane图书馆、中国知网和科学网）进行检索，截止日期为2016年1月1日。根据研究之间的异质性采用随机或固定效应模型。通过Begg漏斗图和Egger回归检验评估潜在的发表偏倚。从157项研究中提取了12项。结果表明，在总体分析中，短重复序列组和长重复序列组之间没有显著差异（I=80.6%，P=0.000，比值比=1.31，95%置信区间：0.93 - 1.83）。在白种人和非裔美国人中，GGN重复序列的长度与前列腺癌的发生均无关联（I=6.7%，P=0.359，比值比=1.11，95%置信区间：0.94 - 1.32；I=74.1%，P=0.050，比值比=0.963，95%置信区间：0.36 - 2.58）。我们的结果表明，与较长的GGN重复序列相比，较短的GGN重复序列多态性不会增加前列腺癌的风险。这与先前的荟萃分析不同。
